Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • Adipose-derived regenerative cells: Phase II started

    Cytori Therapeutics Inc.(NASDAQ:CYTX; Xetra:XMPA), San Diego, Calif. Product: Adipose-derived regenerative cells (ADRCs) (Cytori Cell Therapy, ECCO-50) Business: Autoimmune Molecular target: Not available Description: …

    Published on 3/2/2015
  • Aironite: Phase IIa amended

    Mast Therapeutics Inc.(NYSE-M:MSTX), San Diego, Calif. Product: Aironite (AIR001) Business: Cardiovascular Molecular target: NA Description: Inhaled nebulized sodium nitrite Indication: Treat pulmonary arterial …

    Published on 3/2/2015
  • Aironite: Phase IIa started

    Mast Therapeutics Inc.(NYSE-M:MSTX), San Diego, Calif. Product: Aironite (AIR001) Business: Cardiovascular Molecular target: NA Description: Inhaled nebulized sodium nitrite Indication: Treat heart failure with …

    Published on 3/2/2015
  • ALRN-6924: Phase I started

    Aileron Therapeutics Inc., Cambridge, Mass. Product: ALRN-6924 Business: Cancer Molecular target: Mdm2 p53 binding protein homolog (MDM2) (HDM2); Mdm4 p53 binding protein homolog (MDM4) (MDMX) Description: Stapled …

    Published on 3/2/2015
  • ARC-AAT: Phase I started

    Arrowhead Research Corp.(NASDAQ:ARWR), Pasadena, Calif. Product: ARC-AAT Business: Hepatic Molecular target: Alpha 1-antitrypsin (AAT) (A1AT) (SERPINA1) Description: Unlocked nucleobase analog (UNA)-containing RNAi …

    Published on 3/2/2015
  • BACE1 inhibitor: Phase I hold

    Vitae Pharmaceuticals Inc.(NASDAQ:VTAE), Fort Washington, Pa. Boehringer Ingelheim GmbH, Ingelheim, Germany Product: BACE1 inhibitor (VTP-37948, BI1181181) Business: Neurology Molecular target: Beta-site APP-cleaving …

    Published on 3/2/2015
  • Blisibimod: Phase III ongoing

    Amgen Inc.(NASDAQ:AMGN), Thousand Oaks, Calif. Anthera Pharmaceuticals Inc.(NASDAQ:ANTH), Hayward, Calif. Zenyaku Kogyo Co. Ltd., Tokyo, Japan Product: Blisibimod (A-623) (formerly AMG 623) Business: Autoimmune …

    Published on 3/2/2015
  • Demcizumab: Phase II started

    OncoMed Pharmaceuticals Inc.(NASDAQ:OMED), Redwood City, Calif. Product: Demcizumab (OMP-21M18) Business: Cancer Molecular target: Delta-like 4 (DLL4) Description: Humanized IgG2 mAb against delta-like 4 (DLL4) …

    Published on 3/2/2015
  • Fluticasone furoate/vilanterol/umeclidinium: Phase III started

    Theravance Inc.(NASDAQ:THRX), South San Francisco, Calif. GlaxoSmithKline plc(LSE:GSK; NYSE:GSK), London, U.K. Product: Fluticasone furoate/vilanterol/umeclidinium (Umeclidinium bromide/fluticasone furoate/vilanterol) …

    Published on 3/2/2015
  • FX006: Phase IIb complete enrollment

    Flexion Therapeutics Inc.(NASDAQ:FLXN), Burlington, Mass. Product: FX006 Business: Neurology Molecular target: NA Description: Sustained-release intra-articular formulation of triamcinolone acetonide (TCA) Indication: …

    Published on 3/2/2015
  • Microgabalin: Phase III started

    Daiichi Sankyo Co. Ltd.(Tokyo:4568), Tokyo, Japan Product: Microgabalin (DS-5565) Business: Neurology Molecular target: NA Description: Oral alpha 2 delta ligand Indication: Treat postherpetic neuralgia (PHN) Endpoint: …

    Published on 3/2/2015
  • Microgabalin: Phase III started

    Daiichi Sankyo Co. Ltd.(Tokyo:4568), Tokyo, Japan Product: Microgabalin (DS-5565) Business: Neurology Molecular target: NA Description: Oral alpha 2 delta ligand Indication: Treat diabetic neuropathic pain Endpoint: …

    Published on 3/2/2015
  • Microgabalin: Phase III started

    Daiichi Sankyo Co. Ltd.(Tokyo:4568), Tokyo, Japan Product: Microgabalin (DS-5565) Business: Neurology Molecular target: NA Description: Oral alpha 2 delta ligand Indication: Treat pain associated with fibromyalgia …

    Published on 3/2/2015
  • MRX-I: Phase II started

    MicuRx Pharmaceuticals Inc., Hayward, Calif. Product: MRX-I Business: Infectious Molecular target: NA Description: Oral oxazolidinone, a bacterial protein biosynthesis inhibitor Indication: Treat acute bacterial skin …

    Published on 3/2/2015
  • NKTR-181: Phase III started

    Nektar Therapeutics(NASDAQ:NKTR), San Francisco, Calif. Product: NKTR-181 Business: Neurology Molecular target: Mu opioid receptor (MOR) (OPRM1) Description: Oral mu opioid receptor (OPRM1; MOR) agonist Indication: …

    Published on 3/2/2015
  • Vibativ telavancin: Phase III started

    Theravance Biopharma Inc.(NASDAQ:TBPH), South San Francisco, Calif. Hikma Pharmaceuticals plc(LSE:HIK), London, U.K. Product: Vibativ telavancin (TD-6424) Business: Infectious Molecular target: Not available Description…

    Published on 3/2/2015
  • A4250: Phase IIa started

    Albireo AB, Gothenburg, Sweden Product: A4250 Business: Hepatic Molecular target: Solute carrier family 10 sodium-dependent bile acid transporter member 2 (SLC10A2) (ASBT) (IBAT) Description: Inhibitor of solute carrier…

    Published on 2/23/2015
  • APL-2: Phase I started

    Apellis Pharmaceuticals Inc., Crestwood, Ky. Product: APL-2 Business: Ophthalmic Molecular target: Complement 3 (C3) Description: Complement 3 (C3) inhibitor Indication: Treat wet age-related macular degeneration (AMD) …

    Published on 2/23/2015
  • Betrixaban: Phase III ongoing

    Portola Pharmaceuticals Inc. (NASDAQ:PTLA), South San Francisco, Calif. Product: Betrixaban (PRT054021) Business: Cardiovascular Molecular target: Factor Xa Description: Oral Factor Xa inhibitor Indication: Hospital and…

    Published on 2/23/2015
  • cAd-EBOZ: Phase II/III started

    GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: cAd-EBOZ Business: Infectious Molecular target: NA Description: Recombinant chimpanzee adenovirus type 3 (cAd3) vector containing segments of genetic …

    Published on 2/23/2015
  • Ganaxolone: Phase II started

    Marinus Pharmaceuticals Inc. (NASDAQ:MRNS), Radnor, Pa. Product: Ganaxolone (CCD-1042) Business: Neurology Molecular target: GABA A receptor Description: Synthetic neurosteroid and derivative of allopregnanolone, a GABA…

    Published on 2/23/2015
  • GLA-SE: Phase I started

    Immune Design Corp. (NASDAQ:IMDZ), Seattle, Wash. Product: GLA-SE (G100) (formerly GL-100, ID-G100) Business: Cancer Molecular target: Toll-like receptor 4 (TLR4) Description: Toll-like receptor 4 (TLR4) agonist …

    Published on 2/23/2015
  • HVTN 100: Phase I/II started

    Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: HVTN 100 Business: Infectious Molecular target: NA Description: Combination of Alvac-HIV (vCP205), a live …

    Published on 2/23/2015
  • Luveniq voclosporin: Pilot trial started

    3SBio Inc., Shenyang, China Aurinia Pharmaceuticals Inc. (TSX:AUP; NASDAQ:AUPH), Victoria, B.C. Endo International plc (NASDAQ:ENDP; TSX:ENL), Dublin, Ireland Product: Luveniq voclosporin (LX211) Business: Autoimmune …

    Published on 2/23/2015
  • MEDI4893: Phase II started

    AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: MEDI4893 Business: Infectious Molecular target: NA Description: mAb targeting a Staphylococcus aureus toxin Indication: Prevent pneumonia caused by …

    Published on 2/23/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993